4800 P3 is effectively fully funded by the WHO. MOU signed with Columbia to manufacture there. 4800 heterologous Prime-Booster is funded by Advaccine. 4802 P1/2 will be externally funded by CEPI, BARDA, or NIAID under HHS pending news. AZN COVID-19 dMAb was funded by DARPA. MERS, Lassa fever are funded by CEPI, stockpiled by DoD, CEPI after P2. Ebola booster is funded by DoD. VGX-3100 was licensed to Apollo in China. C2K was licensed to Apollo in SK for $37M per GeneOne. JK said GBM success would expand collaboration with REGN to new diseases.
4802 will likely become a Blockbuster.
Many NGOs and BPs know that and are very interested in it. Hope BPs don’t resort to hostile takeover as Sanofi has done for the following CV vaccine company.
Sanofi acquired all outstanding shares of Translate Bio for $38.00 per share in cash, representing a total equity value of about $3.2 billion.
Ino has a deep pipeline and several platforms.
“In terms of funding for 4800 P3 trial we are asking various parties for support and are also considering doing the P3 together with Advaccine in order to save on costs.
Various NGOs have expressed interest in our 4802 program; now, it can be a long road from interest to actual financial support but we are trying to do everything possible to minimize our burn rate. We hope that today’s pre print is the first step on that road.
We are working with our CRO to select and prepare required documents to agencies of various nations where we are targeting our P3 trial. We are hoping to have additional news to share with you in the coming days and weeks.” 5/12/21
“We have begun talks with various organizations like CEPI, Barda, etc for the support of our INO-4802. Hopefully, we will receive a positive response....” 4/15/21
